NCT04726228 Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE)
| NCT ID | NCT04726228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Naples |
| Condition | Oncology |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-06-21 |
| Primary Completion | 2022-02-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2021-06-21 with a primary completion date of 2022-02-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In cancer patients, the integration between anticancer therapies and palliative care is of fundamental importance. In this context, telemedicine can improve the quality of life (QoL) of chronic patients through self-management and remote monitoring solutions. This approach can favor the effectiveness of the treatment and therapeutic adherence. Of note, telemedicine can also be applied to the management of cancer pain. In the advanced stages of cancer disease, pain is one of the most obvious and most disabling symptoms. Consequently, proper pain management has a significant impact on the QoL, the ability to withstand treatment, and the recovery of patients. On the other hand, given the complexity of cancer pain, the main obstacle to its proper management is the lack of adequate measurement methods. Although in recent years a great deal of effort has been made in the direction of automatic pain assessment, both concerning the creation of datasets and the development of classification algorithms, the literature is lacking regarding the automatic measurement of pain in the setting of cancer patients. Observation by experienced clinical staff and self-assessment by patients could be useful for obtaining the ground truth and, in turn, for training automatic pain recognition systems.
Eligibility Criteria
Inclusion Criteria: * Patients aged \> 18 years * Home care patients diagnosed with advanced cancer disease and life expectancy ≤ 1 year * Patients receiving treatment for cancer pain * Patients who have given their consent Exclusion Criteria: * Patients aged \< 18 years * Willingness to sign the informed consent form (unable to read or write) * Cognitive deficit (e.g. Alzheimer disease or senile dementia)
Contact & Investigator
Marco Cascella, MD
PRINCIPAL INVESTIGATOR
Anesthesia and Pain Medicine. Istituto Nazionale Tumori - IRCCS Fondazione Pascale - Napoli, Italy
Frequently Asked Questions
Who can join the NCT04726228 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04726228 currently recruiting?
Yes, NCT04726228 is actively recruiting participants. Contact the research team at m.cascella@istitutotumori.na.it for enrollment information.
Where is the NCT04726228 trial being conducted?
This trial is being conducted at Naples, Italy, Naples, Italy.
Who is sponsoring the NCT04726228 clinical trial?
NCT04726228 is sponsored by National Cancer Institute, Naples. The principal investigator is Marco Cascella, MD at Anesthesia and Pain Medicine. Istituto Nazionale Tumori - IRCCS Fondazione Pascale - Napoli, Italy. The trial plans to enroll 40 participants.